Published 22 July 2008, doi:10.1136/bmj.a897
Cite this as: BMJ 2008;337:a897

Letters

Cancer drugs and copayments

Paradox of complementary medicine

The first 100% of the full text of this article appears below.

Finlay and Crisp do not resolve the paradox that continued NHS cancer treatment is put at risk if it is topped up with effective, but very expensive, drugs while toppingup with ineffective complementary therapies is positively encouraged.1

If aromatherapy were extremely costly would it be proscribed? Or would it be permitted because it was useless?

Cite this as: BMJ 2008;337:a897

John Doherty, medical director

1 IAEA, Vienna 1400, Austria

dr.johndoherty@gmail.com

Competing interests: None declared.

  1. Finlay I, Crisp N. Drugs for cancer and copayments. BMJ 2008;337:a527. (30 June.)[Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Drugs for cancer and copayments
Ilora Finlay and Nigel Crisp
BMJ 2008 337: a527. [Extract] [Full Text]

Access all current jobs at BMJ Group
Whats new online at Student BMJ
Listen to the latest BMJ Interview